MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.jaut.2025.103471

Медицинская библиотека · Journal of autoimmunity · 2025

FAPI PET/CT for tracking disease trajectory in myositis-related interstitial lung disease.

Kastrati Kastriot, Pochepnia Svitlana, Kulterer Oana C, Nakuz Thomas S, Mrak Daniel, Gessl Irina, Simader Elisabeth, Prayer Florian, Prosch Helmut, Nics Lukas, Schmitl Stefan, Aletaha Daniel, Lechner-Radner Helga, Hacker Marcus, Mandl Peter

СтатьяНаблюдательное исследованиеПеревод в очереди

Аннотация

BACKGROUND

Interstitial lung disease (ILD) is associated with morbidity and mortality in idiopathic inflammatory myopathies (IIM). Predicting ILD progression remains a significant challenge, as conventional diagnostic tools such as pulmonary function tests (PFTs) and high-resolution computed tomography (HRCT) have limited prognostic accuracy. This study evaluated whether 68Ga-labelled inhibitor of Fibroblast-Activation-Protein (FAPI) based PET/CT at baseline predicts ILD evolution over two years.

MATERIAL AND

METHODS

In this prospective observational study, n = 19 individuals with IIM (n = 14 with ILD) underwent [68Ga] Ga-FAPI PET/CT at baseline. ILD progression was defined by three criteria: (1) FVC decline ≥10 % or FVC 5-9 % plus DLCO decline ≥15 %, (2) INBUILD criteria, and (3) a composite endpoint including INBUILD plus therapy escalation, hospitalization, or mortality. Pulmonary tracer uptake was quantified by calculating the maximum and mean target-to-background ratios across the whole lung (wlTBRmax and wlTBRmean, respectively), derived from standardized uptake values corrected for blood pool activity, and their predictive value was analysed.

RESULTS

Over two years, n = 4 (28.6 %) patients met PFT-based progression criteria, while n = 6 (42.9 %) fulfilled INBUILD criteria, and n = 8 (57.1 %) reached the composite endpoint. Baseline wlTBRmax was significantly higher in INBUILD progressors compared to non-progressors (2.68 ± 1.06 vs. 1.59 ± 0.80, p = 0.04), as was wlTBRmean (0.58 ± 0.22 vs. 0.34 ± 0.10, p = 0.04). Similarly, patients meeting the composite endpoint had higher wlTBRmax (2.63 ± 1.04 vs. 1.30 ± 0.31; p < 0.01) and wlTBRmean (0.55 ± 0.20 vs. 0.31 ± 0.09; p = 0.01). Logistic regression analysis showed that incorporating pulmonary wlTBRmax and wlTBRmean enhanced the predictive accuracy over PFT and HRCT alone.

CONCLUSION

FAPI PET/CT may serve as a non-invasive biomarker for early prediction of ILD progression in IIM, supporting personalized disease management. However, given the small, single-centre cohort, these findings should be considered as preliminary and require validation in larger, multi-centre studies.

Для цитирования: Kastrati Kastriot, Pochepnia Svitlana, Kulterer Oana C, Nakuz Thomas S, Mrak Daniel, Gessl Irina, Simader Elisabeth, Prayer Florian, Prosch Helmut, Nics Lukas, Schmitl Stefan, Aletaha Daniel, Lechner-Radner Helga, Hacker Marcus, Mandl Peter. FAPI PET/CT for tracking disease trajectory in myositis-related interstitial lung disease.. Journal of autoimmunity. 2025. DOI: 10.1016/j.jaut.2025.103471.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.